secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001171843-26-002960
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst licenses navenibart to Neopharmed Gentili in Europe for $70M upfront plus milestones
--------------------------------------------------------------------------------

- BioCryst receives $70M upfront and up to $275M in regulatory/sales milestones from Neopharmed Gentili affiliate.
- Tiered royalties on net sales of navenibart in Europe range from 18% to 30%.
- Navenibart Phase 3 in hereditary angioedema on track for US regulatory filing by end of 2027.
- Agreement builds on prior 2025 deal for sale of European ORLADEYO business to Neopharmed Gentili.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184326002960/0001171843-26-002960-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184326002960/f8k_050426.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-002960

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer